Attenuating IL-36 signaling with a small molecule inhibitor could provide moderate-to-severe psoriasis patients with an alternate therapy to currently clinically approved therapies such as the oral PDE4 inhibitor apremilast or the systemic biologics treatments. The gene discussed is PDE4A; the disease is psoriasis.